BioMarin's Q1: Mixed Results, Upgraded Guidance

BioMarin Pharmaceuticals Q1 earnings missed expectations with revenue at $766.2M, up 2.8% YoY but short of $776M forecast, and adjusted EPS at $0.76, missing $0.91 estimate due to manufacturing issues and Amicus acquisition costs. Margins dropped to 16.9% from 30% last year. The company raised full-year revenue guidance to $3.88B, up 14.8% from before, but trimmed adjusted EPS to $4.95. Theyre focusing on Amicus integration, new drugs, and clinical data for upcoming products. Margin recovery and regulatory moves could drive stock momentum. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/ad7d7e64420f3557